• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Study: Wearables Increased Referral Rate for Advanced Therapy in Parkinson’s Disease

by Fred Pennic 07/21/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Wearables in Parkinson’s Disease

Great Lakes NeuroTech has completed and published a clinical study validating that remote monitoring with wearable, objective sensors can lead to an increased referral rate for advanced therapies in Parkinson’s disease.

Published in The Journal of Parkinson’s Disease, the protocol followed 40 patients with Parkinson’s disease randomized into two groups for one year.  The control group received standard care for assessing Parkinson’s disease, while the other used wearable, objective sensors (Kinesia™) in the home environment.

Kinesia ONE uses an app and wireless sensors to objectively measures movement disorders such as Parkinson’s Disease. The sensor and app measures tremor, bradykinesia, and dyskinesia Additionally, during specific tasks, the system can be integrated into clinical trials or patient care.

For the Kinesia group, clinicians remotely viewed reports detailing motor symptoms and dyskinesia throughout the day via a web portal to aid in disease management decisions.  The results demonstrated a clinician was 5 times more likely to recommend a patient for an advanced therapy such as deep brain stimulation (DBS) or an implantable medication pump when given access to objective, remote monitoring reports.  The referral rate for the Kinesia group was 63.6% compared to 11.8% in the standard care group.

The study demonstrated that, when measured remotely, specific variables such as symptom severity and fluctuations of motor symptoms could provide key information to clinicians about when it was time to consider an advanced therapy.

“An important reason we developed and validated our Kinesia technology was to give clinicians a window into what happens when individuals with Parkinson’s disease leave the clinic,” says Dustin Heldman, Biomedical Research Manager in a statement. “The results of this study are advancing our technology beyond the initial building blocks of algorithm validation and usability.  We are now seeing the technology deployed and validated in targeted applications to help guide clinical decision making and improve patient care.  Getting the right therapy to patients at the right time is one of those targeted apps , in which Kinesia can have a significant positive impact.”  

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |